Biomarker · Gene alteration

KRAS G12C

KRAS codon 12 point mutation p.G12C detected by sequencing or PCR in tumor tissue or plasma; used as a predictive marker for KRAS G12C inhibitors in non-small cell lung and colorectal cancer.

CI-BIO-00000015KRAS graph →NCIt C98365

Also calledp.G12C · KRAS G12C-mutated · c.34G>T

Derived

Associated cancers (6)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	7	7	—	—	2 / 2 / 1 / 2 / 0
Lung Non-Small Cell Carcinoma	4	3	1	—	1 / 3 / 0 / 0 / 0
Multiple Myeloma	3	3	—	—	0 / 0 / 0 / 3 / 0
Malignant Lung Neoplasm	2	1	—	1	0 / 2 / 0 / 0 / 0
Malignant Neoplasm

Derived

Drugs with predictive evidence (15)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
MelphalanSmall Molecule	3	—	3	D	0 / 3	Multiple Myeloma
AdagrasibSmall Molecule	2	2	—	A	2 / 0	Malignant Colorectal Neoplasm, Solid Neoplasm
Cetuximab

Curated evidence

Predictive evidence items (16)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–16 of 16 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS G12C16
Divarasib

Regulatory

Approvals mentioning the linked drugs (168)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Adagrasib	US FDA	—	Efficacy supplement 2024-06-21 (see label)	approved	Jun 21, 2024	openfda
Adagrasib	US FDA	Lung Non-Small Cell Carcinoma	Non-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy.	approved	Dec 12, 2022	openfda
Adagrasib	US FDA	—	*These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials.accelerated	approved	Dec 12, 2022	openfda
Adagrasib	US FDA	Malignant Colorectal Neoplasm	Colorectal cancer (CRC)* • In combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.	approved	Dec 12, 2022	openfda
Cetuximab	US FDA	—	Efficacy supplement 2021-09-24 (see label)	approved	Sep 24, 2021	openfda
Cetuximab	US FDA	—	Efficacy supplement 2021-04-06 (see label)	approved	Apr 6, 2021	openfda
Cetuximab	US FDA	—	Efficacy supplement 2021-04-06 (see label)	approved	Apr 6, 2021	openfda
Cetuximab	US FDA	—	Efficacy supplement 2012-07-06 (see label)	approved	Jul 6, 2012	openfda
Cetuximab	US FDA	—	Efficacy supplement 2011-11-07 (see label)	approved	Nov 7, 2011	openfda
Cetuximab	US FDA	—	Efficacy supplement 2007-10-02 (see label)	approved	Oct 2, 2007	openfda
Cetuximab	US FDA	—	Efficacy supplement 2006-03-01 (see label)	approved	Mar 1, 2006	openfda
Cetuximab	US FDA	—	Efficacy supplement 2006-03-01 (see label)	approved	Mar 1, 2006	openfda
Cetuximab	US FDA	Malignant Colorectal Neoplasm	Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.	approved	Feb 12, 2004	openfda
Cetuximab	US FDA	Malignant Colorectal Neoplasm	Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.	approved	Feb 12, 2004	openfda
Cetuximab	US FDA	Head and Neck Squamous Cell Carcinoma	Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.	approved	Feb 12, 2004	openfda
Cetuximab	US FDA	Head and Neck Squamous Cell Carcinoma	Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil.	approved	Feb 12, 2004	openfda
Cetuximab	US FDA	Head and Neck Squamous Cell Carcinoma	Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.	approved	Feb 12, 2004	openfda
Docetaxel	US FDA	Malignant Breast Neoplasm	Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC	approved	Oct 23, 2024	openfda
Docetaxel	US FDA	Head and Neck Squamous Cell Carcinoma	Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN	approved	Oct 23, 2024	openfda
Docetaxel	US FDA	Gastric Adenocarcinoma	Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction	approved	Oct 23, 2024	openfda
Docetaxel	US FDA	Castration-Resistant Prostate Carcinoma	Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer	approved	Oct 23, 2024	openfda
Docetaxel	US FDA	Lung Non-Small Cell Carcinoma	Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC	approved	Oct 23, 2024	openfda
Docetaxel	US FDA	Gastric Adenocarcinoma	Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction	approved	Nov 22, 2022	openfda
Docetaxel	US FDA	Lung Non-Small Cell Carcinoma	Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC	approved	Nov 22, 2022	openfda
Docetaxel	US FDA	Malignant Breast Neoplasm	Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC	approved	Nov 22, 2022	openfda
Docetaxel	US FDA	Castration-Resistant Prostate Carcinoma	Castration- Resistant Prostate Cancer (CRPC) : with prednisone in metastatic CRPC	approved	Nov 22, 2022	openfda
Docetaxel	US FDA	Head and Neck Squamous Cell Carcinoma	Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN	approved	Nov 22, 2022	openfda
Docetaxel	US FDA	—	Efficacy supplement 2019-01-08 (see label)	approved	Jan 8, 2019	openfda
Docetaxel	US FDA	—	Efficacy supplement 2014-07-10 (see label)	approved	Jul 10, 2014	openfda
Docetaxel	US FDA	Lung Non-Small Cell Carcinoma	Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC	approved	Apr 12, 2013	openfda
Docetaxel	US FDA	Head and Neck Squamous Cell Carcinoma	Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN	approved	Apr 12, 2013	openfda
Docetaxel	US FDA	Gastric Adenocarcinoma	Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction	approved	Apr 12, 2013	openfda
Docetaxel	US FDA	Castration-Resistant Prostate Carcinoma	Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer	approved	Apr 12, 2013	openfda
Docetaxel	US FDA	Malignant Breast Neoplasm	Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC	approved	Apr 12, 2013	openfda
Docetaxel	US FDA	Lung Non-Small Cell Carcinoma	Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC	approved	Jun 29, 2011	openfda
Docetaxel	US FDA	Gastric Adenocarcinoma	Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction	approved	Jun 29, 2011	openfda
Docetaxel	US FDA	Castration-Resistant Prostate Carcinoma	Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer	approved	Jun 29, 2011	openfda
Docetaxel	US FDA	Malignant Breast Neoplasm	Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC	approved	Jun 29, 2011	openfda
Docetaxel	US FDA	Head and Neck Squamous Cell Carcinoma	Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN	approved	Jun 29, 2011	openfda
Docetaxel	US FDA	Lung Non-Small Cell Carcinoma	Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC	approved	Jun 8, 2011	openfda
Docetaxel	US FDA	Malignant Breast Neoplasm	Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC	approved	Jun 8, 2011	openfda
Docetaxel	US FDA	Castration-Resistant Prostate Carcinoma	Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer	approved	Jun 8, 2011	openfda
Docetaxel	US FDA	Gastric Adenocarcinoma	Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction	approved	Jun 8, 2011	openfda
Docetaxel	US FDA	Head and Neck Squamous Cell Carcinoma	Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN	approved	Jun 8, 2011	openfda
Docetaxel	US FDA	Lung Non-Small Cell Carcinoma	Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC	approved	May 3, 2011	openfda
Docetaxel	US FDA	Castration-Resistant Prostate Carcinoma	Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer	approved	May 3, 2011	openfda
Docetaxel	US FDA	Gastric Adenocarcinoma	Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction	approved	May 3, 2011	openfda
Docetaxel	US FDA	Head and Neck Squamous Cell Carcinoma	Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN	approved	May 3, 2011	openfda
Docetaxel	US FDA	Malignant Breast Neoplasm	Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC	approved	May 3, 2011	openfda
Docetaxel	US FDA	Castration-Resistant Prostate Carcinoma	Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer	approved	Mar 8, 2011	openfda

Associated cancers (6)

Drugs with predictive evidence (15)

Predictive evidence items (16)

Approvals mentioning the linked drugs (168)

Active trials (279)

Linked publications (17)